Viewing Study NCT06584942



Ignite Creation Date: 2024-10-26 @ 3:39 PM
Last Modification Date: 2024-10-26 @ 3:39 PM
Study NCT ID: NCT06584942
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-09-03

Brief Title: Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients with Cannabis Use Disorder Pilot Study
Sponsor: None
Organization: None

Study Overview

Official Title: Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients with Cannabis Use Disorder
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this study is to observe the impact of suvorexant sold as BELSOMRA on brain activity of people who frequently use cannabis Suvorexant is an FDA-approved medication to treat insomnia We think that suvorexant may reduce activity in certain parts of the brain associated with cannabis use We are studying if this medication does affect brain activity in these areas

For this study we will ask participants to complete four study visits over approximately 14 days Each study visit will include interviews and questionnaires All participants will be asked to take suvorexant an FDA approved medication for treatment of insomnia for 14 days They will complete two one-hour functional Magnetic Resonance Imaging fMRI scans one before starting the study medication and one after 14 days of taking the study medication MRI is used in typical medical settings and is considered to be safe
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None